Re: The Effects of 5α-Reductase Inhibitors on the Natural History, Detection and Grading of Prostate Cancer: Current State of Knowledge. G. Andriole, D. Bostwick, F. Civantos, J. Epstein, M. S. Lucia, J. McConnell and C. G. Roehrborn J Urol, 174: 2098-2104, 2005

Journal of Urology

Volumn 176, Issue 1, 2006, Pages 408-409

  Pitts Jr , W Reid ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTROGEN; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; ANTIANDROGEN; CHOLESTENONE 5ALPHA REDUCTASE; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GRADING; CELL PROLIFERATION; DRUG EFFECT; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECTUM BIOPSY; DRUG ANTAGONISM; MALE; METABOLISM; NOTE; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33744551497     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(06)00577-5     Document Type: Letter

References (21)

1. Luo J., Dunn T.A., Ewing C.M., Walsh P.C., and Isaacs W.B. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer. implications for finasteride therapy of prostate carcinoma. Prostate 57 (2003) 134
2. Clark R.V., Hermann D.J., Cunningham G.R., Wilson T.H., Morrill B.B., and Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179
3. Chang S.M., and Chung L.W. Interaction between prostatic fibroblast and epithelial cells in culture. role of androgen. Endocrinology 125 (1989) 2719
4. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
5. Rubin M.A., Allory Y., Molinie V., Leroy X., Faucon H., Vacherot F., et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 66 (2005) 930
6. Andriole G.L., Guess H.A., Epstein J.I., Wise H., Kadmon D., Crawford E.D., et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 52 (1998) 195
7. Civantos F., Watson R.B., Pinto J.E., Korman R.B., and Soloway M.S. Finasteride effect on prostatic hyperplasia and prostate cancer. a comparative clinico-pathologic study of radical prostatectomies. J Urol Pathol 6 (1997) 1
8. Carver B.S., Kattan M.W., Scardino P.T., and Eastham J.A. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 95 (2005) 509
9. Walsh P.C. Editorial comment. J Urol 171 (2004) 506
10. Pitts Jr. W.R. Letter to the editor. BJU Int 93 (2004) 1120
11. Iczkowski K.A., Qiu J., Qian J., Somerville M.C., Rittmaster R.S., Andriole G.L., et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 65 (2005) 76
12. Pitts Jr. W.R. Re. Chemoprevention of urological cancer [letter to the editor]. J Urol 163 (2000) 1260
13. Pitts Jr. W.R. Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer. a clinical perspective. BJU Int 88 (2001) 985
14. Iehle C., Radvanyi F., Gil Diez de Medina S., Ouafik L.H., Gerard H., Chopin D., et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 68 (1999) 189
15. Thomas L.N., Douglas R.C., Vessey J.P., Gupta R., Fontaine D., Norman R.W., et al. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 170 (2003) 2019
16. Thomas L.N., Lazier C.B., Gupta R., Norman R.W., Troyer D.A., O'Brien S.P., et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63 (2005) 231
17. Lazier C.B., Thomas L.N., Douglas R.C., Vessey J.P., and Rittmaster R.S. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 58 (2004) 130
18. Bologna M., Muzi P., Biordi L., Festuccia C., and Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 45 (1995) 282
19. Andriole G., Lieber M., Smith J., Soloway M., Schroeder F., Kadmon D., et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 45 (1995) 491
20. Lucia M.S., Darke A., Goodman P., Tangen C., Coltman C.A., and Thompson I.M. Pathological assessment of high grade tumors in the Prostate Cancer Prevention Trial (PCPT). J Urol, suppl. 173 (2005) 451 abstract 1664
21. Kulkarni G.S., Al-Azab R., Lockwood G., Toi A., Evans A., Trachtenberg J., et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175 (2006) 505